A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
NCT ID: NCT01277666
Last Updated: 2017-09-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
608 participants
INTERVENTIONAL
2010-12-20
2013-07-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is planned to randomise approximately 600 subjects (200 subjects/group) with active Crohn's disease, diagnosed for at least 4 months with a documented history of disease in the small and/or large intestine, and characterised by a Crohn's Disease Activity Index (CDAI) score between 220 to and 450, inclusive. Subjects must have reported an inadequate response or intolerance to Crohn's disease treatment with corticosteroids or immunosuppressants. Inclusion of subjects who received prior treatment with a biologic anti-tumour necrosis factor (TNF) agent will be limited to approximately 50% of the study population. All subjects are required to have a diagnosis with identification of anatomic location of Crohn's disease, which has been established by visualisation of the gastrointestinal tract within 12 months of screening. Subjects who have not had a visualisation of the gastrointestinal tract within 12 months are required to undergo an endoscopic assessment during the screening period. Subjects will be required to have evidence of current active inflammation at the time of randomisation either by endoscopy or by inflammatory biomarkers \[elevated C-reactive protein (CRP) greater than the upper limit of normal (ULN) plus a positive faecal calprotectin test\]. Subjects who do not meet the requirements based on inflammatory biomarker test results will be required to qualify based on endoscopic assessment during screening. Subjects will be allowed to participate in the study while continuing on stable doses of agents typically used to treat Crohn's disease. Following the screening period, subjects will be randomised at baseline to receive blinded treatment with one of two doses of GSK1605786A (500 mg once daily or twice daily) or placebo for 12 weeks. Response and remission endpoints, using the CDAI, will be evaluated at Weeks 4, 8 and 12.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
orally administered
Placebo
Placebo capsules, administered orally for 12 weeks
GSK1605786A 500mg once daily
orally administered
GSK1605786A
500 mg once daily, administered orally for 12 weeks
GSK1605786A 500mg twice daily
orally administered
GSK1605786A
500 mg twice daily, administered orally for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GSK1605786A
500 mg twice daily, administered orally for 12 weeks
GSK1605786A
500 mg once daily, administered orally for 12 weeks
Placebo
Placebo capsules, administered orally for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
* Diagnosis of Crohn's disease for greater than 4 months duration with small bowel and/or colonic involvement
* Confirmation of Crohn's disease established by visualisation of the gastrointestinal tract within the 12 months prior to screening or by screening endoscopy at study entry
* History of inadequate response and/or intolerance/adverse event leading to discontinuation of either corticosteroids or immunosuppressants
* Moderately-to-severely active disease characterised by a CDAI score between 220 and 450, inclusive, at Baseline
* Confirmation of current active Crohn's disease by screening endoscopy or inflammatory biomarkers \[elevated C-reactive protein (greater than upper limit of normal) plus positive test for faecal calprotectin\] at Screening
* Stable doses of permitted concomitant medications or having previously received, but are not currently receiving, medications for Crohn's disease
* Demonstrated ability to comply with Crohn's disease symptom recording using the interactive voice response system
* Females of child-bearing potential must be sexually inactive or commit to consistent and correct use of a contraceptive method of birth control with a failure rate of less than 1% for the duration of this study
Exclusion Criteria
* Diagnosis of coeliac disease, follow a gluten-free diet to manage symptoms, or positive test for coeliac disease
* Diagnosis of ulcerative or indeterminate colitis
* Enterocutaneous, abdominal or pelvic fistulae with abscesses or fistulae likely to require surgery during the study period
* Bowel surgery, other than appendectomy, within 12 weeks prior to screen and/or has surgery planned or deemed likely for Crohn's disease during the study period
* Extensive colonic resection, subtotal or total colectomy
* Presence of ileostomies, colostomies or rectal pouches
* Known fixed symptomatic stenoses
* History of more than 3 small bowel resections or diagnosis of short bowel syndrome
* Chronic use of narcotics for chronic pain defined as daily use of one or more doses of narcotic containing medication
* Use of prohibited medications, including enteral feeding or elemental diet, within their specified time frames
1. Biologic use: Use of any biologic (tumour necrosis factor inhibitor or natalizumab) within 8 weeks prior to screening
2. Corticosteroid use: Use of parenteral glucocorticoids within 4 weeks prior to screening
3. Immunospressant use: Use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil within 4 weeks prior to screening
4. Intravenous antibiotic use: Use of intravenous antibiotics for Crohn's disease within 4 weeks prior to screening
5. Use of rectal treatment with 5-ASA or corticosteroid enemas/suppositories within 2 weeks prior to screening
6. Use of tube or enteral feeding, elemental diet, or parenteral alimentation within 2 weeks prior to screening
7. Leukocytapheresis or granulocytapheresis within 2 weeks prior to screening
* Positive immunoassay for Clostridium difficile
* Known human immunodeficiency virus (HIV) infection
* Known varicella, herpes zoster, or other severe viral infection within 6 weeks of screening
* Immunisation with a live vaccine within 4 weeks of screening, with the exception of influenza vaccine
* Active or latent tuberculosis infection
* Current sepsis or infections requiring intravenous antibiotic therapy for more than 2 weeks
* Evidence of hepatic dysfunction, viral hepatitis, or current or chronic history of liver disease including non-alcoholic steatohepatitis (NASH)
* Positive test for Hepatitis B or Hepatitis C antibody at screening
* Corrected QT interval of ECG (electrocardiogram) greater than or equal to 450 milliseconds
* Concurrent illness or disability that may affect the interpretation of clinical data, or otherwise contraindicates participation in this clinical study
* History or evidence of adenomatous colonic polyps that have not been removed
* History of evidence of colonic mucosal dysplasia
* Current evidence of, or has been treated for a malignancy within the past five years (other than localised basal cell, squamous cell skin cancer, cervical dysplasia, or any cancer in situ that has been resected)
* Any previous participation in a clinical study of GSK1605786A (formerly ChemoCentryx compound CCX282-B)
* Medical history of sensitivity to any of the components of GSK1605786A
* Use of any investigational product within 30 days prior to screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Little Rock, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Anaheim, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
Lakewood, Colorado, United States
GSK Investigational Site
Littleton, Colorado, United States
GSK Investigational Site
Hamden, Connecticut, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Maitland, Florida, United States
GSK Investigational Site
Port Orange, Florida, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Oak Lawn, Illinois, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Hammond, Louisiana, United States
GSK Investigational Site
Monroe, Louisiana, United States
GSK Investigational Site
Chevy Chase, Maryland, United States
GSK Investigational Site
Towson, Maryland, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Ann Arbor, Michigan, United States
GSK Investigational Site
Chesterfield, Michigan, United States
GSK Investigational Site
Troy, Michigan, United States
GSK Investigational Site
Rochester, Minnesota, United States
GSK Investigational Site
Jackson, Mississippi, United States
GSK Investigational Site
Tupelo, Mississippi, United States
GSK Investigational Site
Lee's Summit, Missouri, United States
GSK Investigational Site
Lebanon, New Hampshire, United States
GSK Investigational Site
Egg Harbor City, New Jersey, United States
GSK Investigational Site
Voorhees Township, New Jersey, United States
GSK Investigational Site
Great Neck, New York, United States
GSK Investigational Site
Chapel Hill, North Carolina, United States
GSK Investigational Site
Durham, North Carolina, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Tulsa, Oklahoma, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Germantown, Tennessee, United States
GSK Investigational Site
Nashville, Tennessee, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Pasadena, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Seattle, Washington, United States
GSK Investigational Site
Seattle, Washington, United States
GSK Investigational Site
Bankstown, New South Wales, Australia
GSK Investigational Site
Hersten, Queensland, Australia
GSK Investigational Site
Adelaide, South Australia, Australia
GSK Investigational Site
Kurralta Park, South Australia, Australia
GSK Investigational Site
Fitzroy, Victoria, Australia
GSK Investigational Site
Prahran, Victoria, Australia
GSK Investigational Site
Fremantle, Western Australia, Australia
GSK Investigational Site
Hall in Tirol, , Austria
GSK Investigational Site
Linz, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Vienna, , Austria
GSK Investigational Site
Bonheiden, , Belgium
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Edegem, , Belgium
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Kortrijk, , Belgium
GSK Investigational Site
Leuven, , Belgium
GSK Investigational Site
Roeselare, , Belgium
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Abbotsford, British Columbia, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Victoria, British Columbia, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Kingston, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Richmond Hill, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Lévis, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Brno, , Czechia
GSK Investigational Site
Hradec Králové, , Czechia
GSK Investigational Site
Olomouc, , Czechia
GSK Investigational Site
Ostrava - Vitkovice, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Aalborg, , Denmark
GSK Investigational Site
Aarhus, , Denmark
GSK Investigational Site
Herlev, , Denmark
GSK Investigational Site
Hvidovre, , Denmark
GSK Investigational Site
Odense, , Denmark
GSK Investigational Site
Amiens, , France
GSK Investigational Site
Clichy, , France
GSK Investigational Site
Lille, , France
GSK Investigational Site
Nantes, , France
GSK Investigational Site
Nice, , France
GSK Investigational Site
Paris, , France
GSK Investigational Site
Pessac, , France
GSK Investigational Site
Saint-Priest-en-Jarez, , France
GSK Investigational Site
Vandœuvre-lès-Nancy, , France
GSK Investigational Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
GSK Investigational Site
Ulm, Baden-Wurttemberg, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Braunschweig, Lower Saxony, Germany
GSK Investigational Site
Brinkum/Stuhr, Lower Saxony, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Cologne, North Rhine-Westphalia, Germany
GSK Investigational Site
Minden, North Rhine-Westphalia, Germany
GSK Investigational Site
Münster, North Rhine-Westphalia, Germany
GSK Investigational Site
Münster, North Rhine-Westphalia, Germany
GSK Investigational Site
Ludwigshafen am Rhein, Rhineland-Palatinate, Germany
GSK Investigational Site
Dessau, Saxony-Anhalt, Germany
GSK Investigational Site
Halle, Saxony-Anhalt, Germany
GSK Investigational Site
Jena, Thuringia, Germany
GSK Investigational Site
Berlin, , Germany
GSK Investigational Site
Berlin, , Germany
GSK Investigational Site
Berlin, , Germany
GSK Investigational Site
Hamburg, , Germany
GSK Investigational Site
Hamburg, , Germany
GSK Investigational Site
Békéscsaba, , Hungary
GSK Investigational Site
Budapest, , Hungary
GSK Investigational Site
Szekszárd, , Hungary
GSK Investigational Site
Haifa, , Israel
GSK Investigational Site
Holon, , Israel
GSK Investigational Site
Jerusalem, , Israel
GSK Investigational Site
Jerusalem, , Israel
GSK Investigational Site
Kfar Saba, , Israel
GSK Investigational Site
Petah Tikva, , Israel
GSK Investigational Site
Tel Aviv, , Israel
GSK Investigational Site
Palermo, Sicily, Italy
GSK Investigational Site
Genova, , Italy
GSK Investigational Site
Modena, , Italy
GSK Investigational Site
Roma, , Italy
GSK Investigational Site
Roma, , Italy
GSK Investigational Site
Aichi, , Japan
GSK Investigational Site
Aichi, , Japan
GSK Investigational Site
Chiba, , Japan
GSK Investigational Site
Fukuoka, , Japan
GSK Investigational Site
Fukuoka, , Japan
GSK Investigational Site
Hokkaido, , Japan
GSK Investigational Site
Hyōgo, , Japan
GSK Investigational Site
Kagoshima, , Japan
GSK Investigational Site
Kagoshima, , Japan
GSK Investigational Site
Miyagi, , Japan
GSK Investigational Site
Osaka, , Japan
GSK Investigational Site
Osaka, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Almere Stad, , Netherlands
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Ede, , Netherlands
GSK Investigational Site
Heerlen, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Auckland, , New Zealand
GSK Investigational Site
Dunedin, , New Zealand
GSK Investigational Site
Hamilton, , New Zealand
GSK Investigational Site
Lower Hutt, , New Zealand
GSK Investigational Site
Otahuhu, , New Zealand
GSK Investigational Site
Tauranga, , New Zealand
GSK Investigational Site
Ålesund, , Norway
GSK Investigational Site
Bodø, , Norway
GSK Investigational Site
Oslo, , Norway
GSK Investigational Site
Tromsø, , Norway
GSK Investigational Site
Trondheim, , Norway
GSK Investigational Site
Tønsberg, , Norway
GSK Investigational Site
Bydgoszcz, , Poland
GSK Investigational Site
Bydgoszcz, , Poland
GSK Investigational Site
Elblag, , Poland
GSK Investigational Site
Lublin, , Poland
GSK Investigational Site
Sopot, , Poland
GSK Investigational Site
Torun, , Poland
GSK Investigational Site
Wroclaw, , Poland
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Nitra, , Slovakia
GSK Investigational Site
Nové Mesto nad Váhom, , Slovakia
GSK Investigational Site
Prešov, , Slovakia
GSK Investigational Site
Trnava, , Slovakia
GSK Investigational Site
Bellville, , South Africa
GSK Investigational Site
Claremont, , South Africa
GSK Investigational Site
Observatory, , South Africa
GSK Investigational Site
Parktown, , South Africa
GSK Investigational Site
Daegu, , South Korea
GSK Investigational Site
Pusan, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Seoul, , South Korea
GSK Investigational Site
Wŏnju, , South Korea
GSK Investigational Site
Badalona, , Spain
GSK Investigational Site
Elche, , Spain
GSK Investigational Site
Galdakao/Vizcaya, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Sabadell (Barcelona), , Spain
GSK Investigational Site
Gothenburg, , Sweden
GSK Investigational Site
Lund, , Sweden
GSK Investigational Site
Stockholm, , Sweden
GSK Investigational Site
Stockholm, , Sweden
GSK Investigational Site
Umeå, , Sweden
GSK Investigational Site
Harrow, Middlesex, United Kingdom
GSK Investigational Site
Birmingham, , United Kingdom
GSK Investigational Site
Bristol, , United Kingdom
GSK Investigational Site
Edinburgh, , United Kingdom
GSK Investigational Site
Manchester, , United Kingdom
GSK Investigational Site
Newcastle upon Tyne, , United Kingdom
GSK Investigational Site
Nottingham, , United Kingdom
GSK Investigational Site
Oxford, , United Kingdom
GSK Investigational Site
Salford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
114151
Identifier Type: -
Identifier Source: org_study_id